Abstract:e15514 Background: Trophoblast cell-surface antigen 2 (TROP2), a transmembrane glycoprotein in epithelial cells, is implicated in malignant progression, notably in breast cancer therapy. However, the clinicopathologic aspects of TROP2 in colorectal cancer (CRC) are unclear. This study aims to explore the association between TROP2 expression and clinicopathological features in CRC and investigate the inhibitory effects of the anti-TROP2 antibody-SN-38 conjugate (ADC-TROP2) on colon cancer cells. Methods: A retrospective analysis of 1296 CRC patients who underwent colorectomy at Renji Hospital, Shanghai Jiaotong University School of Medicine, was conducted. Immunohistochemistry determined the expressions of TROP2, HER2, and PD-L1 in colon cancer tissues. Statistical analyses, including the chi-square test and Cox proportional hazards model, assessed associations. Sacituzumab Govitecan (ADC-TROP2 drug) cytotoxicity on human cancer cells was determined using the MTT method. Results: TROP2 was predominantly expressed at the cell membrane of cancer tissues, with 50% of cases TROP2-positive. The overexpression of TROP2 (staining extension 2+ or 3+) were found in 356 (27.5%) cases. The clinicopathological features of all 1296 patients based on the TROP2 expression in their cancer cells were summarized in Table 1. Compared to TROP2 negativity expression, the high TROP2 expression was significantly associated with the advantaged tumor stage (III/IV, P = 0.022), high tumor invasion depth (T3/T4, P = 0.002), lymph node metastasis (N1/N2, p = 0.026), HER-2 expression (2+/3+, p = 0.013) ,PD-L1 CPS (CPS≤5,P = 0.007). Sacituzumab Govitecan exhibited stronger inhibition in TROP2-positive human CRC cells in TROP2-negative CRC cells compared to TROP2-negative cells and the control SN-38 agent. Conclusions: TROP2 expression positive in 50% of CRC cases is associated with with advantaged tumor stage, high tumor invasion depth, lymph node metastasis. Sacituzumab Govitecan demonstrates potent targeting of TROP2-positive CRC cells, suggesting TROP2 as a potential biomarker for clinical prognosis and therapeutic targeting in colon cancer. [Table: see text]

Different Effects of ERβ and TROP2 Expression in Chinese Patients with Early-Stage Colon Cancer

Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type

Impact of ERβ and CD44 Expression on the Prognosis of Patients with Stage II Colon Cancer

Prognostic Impact of ERβ and MMP7 Expression on Overall Survival in Colon Cancer

Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway

[Relationship Between the Protein Expression of P53, C-Erbb-2, Vascular Endothelial Growth Factor and CD44 and the Survival Rates of Stage II( Colorectal Cancer Patients Without Radiochemotherapy after Radical Resection].

Period 1 and Estrogen Receptor-Beta Are Downregulated in Chinese Colon Cancers.

Prognostic Impact Of Er Beta And Mmp7 Expression On Overall Survival In Colon Cancer

Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.

Colorectal Cancer: Clinicopathological Characteristics and Prognostic Factors

Decreased E2F2 Expression Correlates with Poor Prognosis and Immune Infiltrates in Patients with Colorectal Cancer

Trophoblast Cell-Surface Antigen 2 is a Biomarker and Potential Therapeutic Target in Human Colon Cancer.

Effect of Growth Factor and Its Receptor and COX-2 Expressions to Progression and Prognosis in Colorectal Carcinoma

Prognostic value of estrogen receptor-α and progesterone receptor in curatively resected colorectal cancer: a retrospective analysis with independent validations

TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection

Expression and its clinical significance of ERCC1 in stage Ⅱ colorectal carcinoma

Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer

Expression and clinical significance of estrogen receptor β and vascular endothelial growth factor in colorectal carcinoma

ERCC1 mRNA expression in relation to prognostic of colorectal cancer patients received the standard first-line chemotherapy

Relationship between expression levels of p53, epidermal growth factor receptor, sex determining region Y-box 2 and prognosis of colorectal cancer after operation

Overexpression Of Trophoblast Cell Surface Antigen 2 As An Independent Marker For A Poor Prognosis And As A Potential Therapeutic Target In Epithelial Ovarian Carcinoma